Preterm births in a resource constrained setting: sociobiologic risk factors and perinatal outcomes

Background: To determine maternal risk factors and perinatal outcomes of preterm births in south-western Nigeria.Methods: A retrospective study of preterm and term deliveries in a tertiary hospital in Nigeria. The delivery records were reviewed and case files of preterm births were identified and retrieved. Perinatal outcomes were determined by review of the postnatal and special care baby unit records. Multivariate logistic regression was carried out to determine factors independently associated with preterm births. Adjusted odds ratios and confidence intervals were determined.Results: The preterm birth rate was 5.7%. Prelabour rupture of membranes was the leading cause of preterm birth, while a third of them were unexplainable. Age >35yrs (AOR 2.16(1.36-3.42)), the unbooked status (AOR 2.52(1.76-3.61)), Previous history of preterm delivery (AOR 6.41(2.48-16.60)), pre-labour rupture of membranes (AOR 11.08(6.01-18.56)), antepartum haemorrhage (AOR 10.91(4.94-24.09)), multiple gestations (AOR 32.23(13.07-79.50)) and hypertension in pregnancy(AOR6.42(3.79-10.88)) were independently associated with preterm delivery. Low birthweight, asphyxia, neonatal intensive care unit admission and perinatal mortality were common among preterm births. The perinatal mortality rate among the preterm neonates was 14.5%.Conclusion: Preterm birth remains a significant cause of perinatal deaths. Strategies addressing potentially modifiable risk factors will reduce the incidence and improve the perinatal outcomes associated with preterm births.Keywords: preterm delivery, prematurity, perinatal mortality, Nigeria

Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.

Pneumococcal conjugate vaccines (PCVs) have been successful in preventing invasive pneumococcal disease but effectiveness has been challenged by replacement of vaccine serotypes with non-vaccine serotypes. Vaccines targeting common pneumococcal protein(s) found in most/all pneumococci may overcome this limitation. This phase II study assessed safety and immunogenicity of a new protein-based pneumococcal vaccine containing polysaccharide conjugates of 10 pneumococcal serotypes combined with pneumolysin toxoid(dPly) and pneumococcal histidine triad protein D(PhtD) (PHiD-CV/dPly/PhtD-30) in African children. 120 Gambian children (2-4 years, not previously vaccinated against Streptococcus pneumoniae) randomized (1:1) received a single dose of PHiD-CV/dPly/PhtD-30 or PCV13. Adverse events occurring over 4 d post-vaccination were reported, and blood samples obtained pre- and 1-month post-vaccination. Serious adverse events were reported for 6 months post-vaccination. Solicited local and systemic adverse events were reported at similar frequency in each group. One child (PHiD-CV/dPly/PhtD-30 group) reported a grade 3 local reaction to vaccination. Haematological and biochemical parameters seemed similar pre- and 1-month post-vaccination in each group. High pre-vaccination Ply and PhtD antibody concentrations were observed in each group, but only increased in PHiD-CV/dPly/PhtD-30 vaccinees one month post-vaccination. One month post-vaccination, for each vaccine serotype ≥96.2% of PHiD-CV/dPly/PhtD-30 vaccinees had serotype-specific polysaccharide antibody concentrations ≥0.20µg/mL except serotypes 6B (80.8%) and 23F (65.4%), and ≥94.1% had OPA titres of ≥8 except serotypes 1 (51.9%), 5 (38.5%) and 6B (78.0%), within ranges seen in PCV13-vaccinated children. A single dose of PHiD-CV/dPly/PhtD-30 vaccine, administered to Gambian children aged 2-4 y not previously vaccinated with a pneumococcal vaccine, was well-tolerated and immunogenic

The financial burden of sickle cell disease on households in Ekiti, Southwest Nigeria

Oladele Simeon Olatunya,1,3 Ezra Olatunde Ogundare,1,3 Joseph Olusesan Fadare,2 Isaac Oludare Oluwayemi,1,3 Oyinkansola Tolulope Agaja,3 Babajide Samson Adeyefa,3 Odunayo Aderiye3 1Department of Paediatrics, Ekiti State University, Ado Ekiti, Nigeria; 2Department of Clinical Pharmacology, Ekiti State University, Ado Ekiti, Nigeria; 3Department of Paediatrics, Ekiti State University Teaching Hospital, Ado Ekiti, Nigeria Background: Studies on economic impact of sickle cell disease (SCD) are scanty despite its being common among children in developing countries who are mostly Africans.Objective: To determine the financial burden of SCD on households in Ado Ekiti, Southwest Nigeria.Methods: A longitudinal and descriptive study of household expenditures on care of 111 children with SCD managed at the pediatric hematology unit of the Ekiti State University Teaching Hospital was conducted between January and December 2014.Results: There were 64 male and 47 female children involved, aged between 15 and 180 months. They were from 111 households, out of which only eight (7.2%) were enrolled under the National Health Insurance Scheme. The number of admissions and outpatients' consultations ranged from 1 to 5 and 1 to 10 per child, respectively. Malaria, vaso-occlusive crisis, and severe anemia were the leading comorbidities. The monthly household income ranged between ₦12,500 and ₦330,000 (US$76 and US$2,000) with a median of ₦55,000 (US$333), and health expenditure ranged between ₦2,500 and ₦215,000 (US$15 and US1,303) with a mean of ₦39,554±35,479 (US240±215). Parents of 63 children lost between 1 and 48 working days due to their children's ill health. Parents of 23 children took loans ranging between ₦6,500 and ₦150,000 (US$39 and US$909) to offset hospital bills. The percentage of family income spent as health expenditure on each child ranged from 0.38 to 34.4. Catastrophic health expenditure (when the health expenditure >10% of family income) occurred in 23 (20.7%) households. Parents who took loan to offset hospital bills, low social class, and patients who took ill during the study period significantly had higher odds for catastrophic health expenditure (95% confidence interval [CI] 5.399–87.176, P=0.000; 95% CI 2.322–47.310, P=0.002; and 95% CI 1.128–29.694, P=0.035, respectively).Conclusion: SCD poses enormous financial burden on parents and households.Keywords: sickle cell disease, family income, health expenditure, financial catastrophe, Nigeri

Demographic survey and management outcome of Post-Neonatal Tetanus at the Ekiti state university teaching hospital, Ado Ekiti

Background: Tetanus continues to threaten the survival of children in spite of it being a vaccine preventable disease. The objective of this study was to determine the prevalence of post-neonatal tetanus, review the vaccination of affected children, complications encountered and the outcome among affected children in a tertiary health institution in southwestern Nigeria. Methods: The study was a retrospective study. Case notes of children outside neonatal life admitted to the Paediatric ward with clinical diagnosis of tetanus between January 2012 and October 2018 were retrieved and evaluated to identify socio-demographic and clinical characteristics. A review of the immunization history and cards was done where the immunization cards were available. Results: 21children with post-neonatal tetanus were admitted over a period of six years (November 2012 to October 2018) with a prevalence of 0.3%. The M:F was 3.2:1. The mean age in years was 10.14 ±3.44 while the age range of the subjects was 4 to 16years. None of the patients had booster doses of tetanus toxoid (TT) outside the infancy period. Nine (42.9%) subjects had no previous TT vaccination, 2 (9.5%) had 3 doses of TT vaccine in infancy but developed tetanus at age ≥9 years, 1(4.8%) subject had a dose of TT while the remaining 9subjects had no proof of previous TT vaccination. The percentage mortality was 19% (4 out of 21). All the patients that died had no prior record of TT vaccination. Complications identified included laryngeal spasm and autonomic dysfunction. Conclusion: Post-neonatal tetanus is still common in our locality because booster doses of Tetanus Toxoid are not part of the national immunization schedule. Complete dose of tetanus toxoid vaccination during infancy and booster doses at school entry is necessary and should be part of school health programme to forestall post-neonatal tetanu